SuperGen Pulls U.S. Cancer Drug Application
18611
SuperGen Inc. on Monday said it has  withdrawn an application to market its pancreatic cancer  treatment in the United States due to insufficient data,  sending its shares down 17 percent.
45979
Americans with prostate cancer are traveling out of the country to receive a treatment that is not approved in the United States.
160780
Roche Holding, the world&#39;s biggest maker of diagnostic tests, has received Food and Drug Administration approval to market the first laboratory gene test that can help doctors reduce the risk of side effects for certain medications.
579429
Novartis AG, Switzerland s largest drugmaker, withdrew an application for European Union approval of its experimental Prexige, a painkiller similar to Merck & Co.
257211
Swiss pharmaceutical giant Novartis AG said Tuesday it is temporarily withdrawing an application for European Union approval of its painkiller Prexige, but added that it will present new data this week to prove the safety and effectiveness of the drug.
454185
GlaxoSmithKline PLC revealed Thursday that the U.S. Food and Drug Administration has declined to grant a priority review to its experimental cancer vaccine Cervarix, adding to pressure on the drug maker after controversy surrounding its diabetes drug Avandia.
585919
The company withdrew its application to gain federal approval for a weight loss drug after a meeting at which government advisers rejected the treatment on safety grounds.
154653
NEW YORK  - Claims for the cancer-preventing potential of tomatoes and lycopene should be sharply limited, the US Food and Drug Administration has concluded.
575085
NEW YORK/FRANKFURT  - A drug being developed by  Bayer AG and Onyx Pharmaceuticals Inc. shrank tumors in some  liver cancer patients and temporarily stabilized the disease in  others in a small clinical trial, the companies said on  Wednesday.
199689
Shares of SuperGen Inc.  dropped 17 percent before the bell on Monday after the company said it withdrew an application to market its pancreatic cancer treatment in the United States due to insufficient data.
619726
AstraZeneca, the Anglo-Swedish pharmaceutical group, suffered another setback when it suspended marketing of Iressa, a lung cancer drug launched this year.
114882
Under pressure for more data on the long-term safety effects of its Intrinsa testosterone patch, Procter &amp; Gamble Co. has withdrawn its application to the US Food and Drug Administration to market the patch.
156273
NEW YORK (CBS.MW) - Shares of GenVec Inc. lost nearly half their value Thursday after the Food and Drug Administration put the company&#39;s TNFerade cancer drug trials on hold.
232138
MGI Pharma Inc. MOGN.O will spend up  to $85 million for a stake in SuperGen Inc. SUPG.O and global  rights to develop and sell SuperGen's experimental drug for an  often-fatal cancer of the bone marrow, the companies said on  Wednesday.
297779
Shares of SuperGen Inc.  jumped more than 24 percent in trading before the market opened on Wednesday after MGI Pharma Inc.  said it would take a &#36;40 million stake in the company as part of a cancer drug license deal.
207035
AstraZeneca Plc has withdrawn its  marketing application for lung cancer pill Iressa in Europe  after the drug failed to help patients live longer in a  clinical study, Europe's third largest drugmaker said on  Tuesday.
445999
The Food and Drug Administration (FDA) learned yesterday from AstraZeneca that a large clinical trial comparing Iressa (gefitinib) with placebo in patients with non-small cell lung cancer who had failed other courses of cancer therapy showed no survival